Ziltivekimab - Novo Nordisk
Alternative Names: COR 001; NN 6018Latest Information Update: 10 May 2024
At a glance
- Originator AstraZeneca
- Developer Novo Nordisk
- Class Anti-inflammatories; Cardiovascular therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cardiovascular disorders; Heart failure; Inflammation; Kidney disorders
Most Recent Events
- 01 Apr 2024 Phase-III clinical trials in Heart failure in Czech Republic, India, United Kingdom (SC) (NCT06200207)
- 01 Apr 2024 Phase-III clinical trials in Inflammation in Czech Republic, India, United Kingdom (SC) (NCT06200207)
- 01 Apr 2024 Novo Nordisk initiates the phase III ATHENA trial for Inflammation in the US, Bulgaria, Canada, Germany, Greece, and Poland (SC) (NCT06200207)